Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Weycker, Derek ^a   Danel, Aurelie ^b   Marciniak, Anne ^c   Bendall, Kate ^d   Lipsitz, Michael ^a   Pettengell, Ruth ^e  

^a POLICY ANALYSIS INC PAI   (United States)

^b AMGEN INC   (United States)

^c AMGEN LTD   (United Kingdom)

^d Biostatistics Cascade   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Costs and cost analysis; Febrile neutropenia; Non Hodgkin's lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUSTRALIAN; CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA; CLINICAL PRACTICE; DRUG COST; ETHNIC GROUP; EUROPEAN; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

EID: 84865175118     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-362     Document Type: Article

References (18)

1. Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 2011, 77:221-40. 10.1016/j.critrevonc.2010.02.002, 20227889.
2. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005, 330:217. 10.1136/bmj.38314.622095.8F, 546063, 15649903.
3. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003, 21:4524-31. 10.1200/JCO.2003.05.002, 14673039.
4. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-205. 10.1200/JCO.2006.06.4451, 16682719.
5. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990, 8:963-77.
6. Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer 1998, 34:1857-64. 10.1016/S0959-8049(98)00222-6, 10023306.
7. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005, 103:1916-24. 10.1002/cncr.20983, 15751024.
8. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106:2258-66. 10.1002/cncr.21847, 16575919.
9. Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G. Cost of neutropenic complications of chemotherapy. Ann Oncol 2008, 19:454-60.
10. Haioun C, Salar A, Pettengell R. Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study. Leuk Lymphoma 2011, 52:796-803. 10.3109/10428194.2011.557166, 21338278.
11. Pettengell R, Johnson HE, Lugtenburg PJ, Silvestre AS, Dührsen U, Rossi FG, Schwenkglenks M, Bendall K, Szabo Z, Jaeger U. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer 2012, 20:647-52. 10.1007/s00520-011-1306-6, 3271211, 22101611.
12. Salar A, Haioun C, Rossi FG, Duehrsen U, Pettengell R, Johnsen HE, Jaeger U, Verhoef G, Schwenkglenks M, Bacon P, Bendall K, Lugtenburg PJ. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP 21: Findings from clinical practice. Leuk Res 2012,
13. Johnsen HE, Haioun C, Lugtenburg. The importance of G-CSF prophylaxis in R-CHOP-14 therapy for diffuse large B-cell lymphoma in routine clinical practice. Leuk Lymphoma 2012,
14. Unit Costs of Health and Social Care Personal Social Services Research Unit (PSSRU) 2010, Available at: http://www.pssru.ac.uk/pdf/uc/uc2010/uc2010.pdf. Accessed on March 1, 2011, Unit Costs of Health and Social Care.
15. CRD and CHE Technology Assessment Group Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer: a single technology appraisal 2010, Centre for Reviews and Dissemination/Centre for Health Economics, CRD and CHE Technology Assessment Group.
16. National Institute for Health and Clinical Excellence, Single Technology Appraisal Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate Available at: http://www.nice.org.uk/nicemedia/live/12970/52220/52220.pdf. Accessed on July 12, 2012, National Institute for Health and Clinical Excellence, Single Technology Appraisal.
17. National Institute for Health and Clinical Excellence, Single Technology Appraisal Cabazitaxel for the second-line treatment of metastatic hormone refractory prostate cancer 2011, Available at: http://www.nice.org.uk/nicemedia/live/13237/56549/56549.pdf. Accessed on July 12, 2012, National Institute for Health and Clinical Excellence, Single Technology Appraisal.
18. Greenhalgh J, Bagust A, Boland A, Fleeman N, McLeod C, Dundar Y, Proudlove C, Shaw R. Cetuximab for metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Single Technology Appraisal 2008, The University of Liverpool: LRiG.